Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.56 |
| ▸ | CTSA | P10619 | 6/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893662 | 0.91 | MDM2 (0.54) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9894220 | 0.88 | MDM2 (0.70) | MDM2CTSAMDM4TP53 | |
| SCHEMBL1438284 | 0.87 | MDM2 (0.60) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9893792 | 0.85 | MDM2 (0.48) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9894076 | 0.85 | MDM2 (0.58) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9893923 | 0.84 | MDM2 (0.63) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9893788 | 0.82 | MDM2 (0.53) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9894216 | 0.81 | MDM2 (0.50) | MDM2CTSAMDM4TP53 | |
| SCHEMBL9893649 | 0.80 | MDM2 (0.52) | MDM2CTSAMDM4TP53 | |
| SCHEMBL1438128 | 0.79 | MDM2 (0.49) | MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885CTSA 1670/4885PTGDR2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.